Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Asset Writedowns and Impairment data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment fell 42.7% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (down 4.84% YoY) and the FY2025 annual result came in at $7.6 million, up 542.08% from the prior year.
• Asset Writedowns and Impairment fell to $1.2 million in Q1 2026 per FLGT's latest filing, from $1.9 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $11.6 million in Q1 2022, with the low at -$2.5 million in Q1 2024.
• Average Asset Writedowns and Impairment over 5 years is $3.7 million, with a median of $2.1 million recorded in 2025.
• Year-over-year, Asset Writedowns and Impairment jumped 987.78% in 2022 and slumped 2109.73% in 2024.
• Fulgent Genetics' Asset Writedowns and Impairment stood at $7.3 million in 2022, then sank by 52.7% to $3.5 million in 2023, then plunged by 57.11% to $1.5 million in 2024, then rose by 25.27% to $1.9 million in 2025, then sank by 35.87% to $1.2 million in 2026.
• Business Quant data shows FLGT's Asset Writedowns and Impairment at $1.2 million in Q1 2026, $1.9 million in Q4 2025, and $9.9 million in Q2 2025.